TRAIL-Troglitazone-induced apoptosis in prostate Cancer Cells involve AMP-activated protein kinase [Signal Transduction]

July 21st, 2015 by Santha, S., Viswakarma, N., Das, S., Rana, A., Rana, B.

Prostate cancer (PCa) is one of the most frequently diagnosed cancers in men with limited treatment options for the hormone-resistant forms. Development of novel therapeutics options is critically needed to target advanced forms. Here we demonstrate that combinatorial treatment with the Thiazolidinedione troglitazone (TZD) and TRAIL can induce significant apoptosis in various PCa cells independent of androgen receptor status. Since TZD is known to activate AMP-activated protein kinase (AMPK), we determined whether AMPK is a molecular target mediating this apoptotic cascade by utilizing PCa cell lines stably overexpressing AMPKα1-dominant negative (C4-2-DN) or empty vector (C4-2-EV). Our results indicated a significantly higher degree of apoptosis with TRAIL-TZD combination in C4-2-EV cells compared to C4-2-DN cells. Similarly, results from MTT assay showed a larger reduction of viability of C4-2-EV cells compared to C4-2-DN cells when treated with TRAIL-TZD, thus suggesting that C4-2-DN cells were more apoptosis resistant. Additionally, small interference RNA (siRNA)-mediated knockdown of endogenous AMPKα1 expression showed a reduction of TRAIL-TZD-induced apoptosis, further confirming the participation of AMPK in mediating this apoptosis. Apoptosis induction by this combinatorial treatment was also associated with a cleavage of β-catenin that was inhibited in both C4-2-DN cells and those cells in which AMPKα1 was knocked down. In addition, time course studies showed an increase in pACCS79 (AMPK target) levels coinciding with the time of apoptosis. These studies indicate the involvement of AMPK in TRAIL-TZD-mediated apoptosis and β-catenin cleavage, and suggest the possibility of utilizing AMPK as a therapeutic target in apoptosis-resistant prostate cancer.